These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2106770)

  • 21. An economic approach to health care.
    Homik JE; Suarez-Almazor M
    Best Pract Res Clin Rheumatol; 2004 Apr; 18(2):203-18. PubMed ID: 15121040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study.
    Kobelt G; Jönsson L; Young A; Eberhardt K
    Rheumatology (Oxford); 2003 Feb; 42(2):326-35. PubMed ID: 12595631
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists.
    Bansback NJ; Regier DA; Ara R; Brennan A; Shojania K; Esdaile JM; Anis AH; Marra CA
    Drugs; 2005; 65(4):473-96. PubMed ID: 15733011
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health services research clinical trials: issues in the evaluation of economic costs and benefits.
    Manheim LM
    Control Clin Trials; 1998 Apr; 19(2):149-58. PubMed ID: 9551279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Economic evaluation of a new treatment for rheumatoid arthritis].
    Suka M; Yoshida K
    Nihon Rinsho; 2007 Jul; 65(7):1327-30. PubMed ID: 17642251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Making smart investment decisions in clinical research.
    Bansback N; Keystone E; O'Dell J; Phibbs CS; Hannagan K; Brophy M; Anis A
    Trials; 2015 Dec; 16():590. PubMed ID: 26712327
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The comparison of trial data-based and registry data-based cost-effectiveness of infliximab treatment for rheumatoid arthritis in Sweden using a modeling approach.
    Lekander I; Kobelt G; Svarvar P; Ljung T; van Vollenhoven R; Borgström F
    Value Health; 2013; 16(2):251-8. PubMed ID: 23538176
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incorporating utility-based quality-of-life assessment measures in clinical trials. Two examples.
    Feeny DH; Torrance GW
    Med Care; 1989 Mar; 27(3 Suppl):S190-204. PubMed ID: 2522159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis.
    Tanno M; Nakamura I; Ito K; Tanaka H; Ohta H; Kobayashi M; Tachihara A; Nagashima M; Yoshino S; Nakajima A
    Mod Rheumatol; 2006; 16(2):77-84. PubMed ID: 16633926
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.
    Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
    Pharmacoeconomics; 2005; 23(4):377-93. PubMed ID: 15853437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Perceived work ability, quality of life, and fatigue in patients with rheumatoid arthritis after a 6-month course of TNF inhibitors: prospective intervention study and partial economic evaluation.
    Hoving JL; Bartelds GM; Sluiter JK; Sadiraj K; Groot I; Lems WF; Dijkmans BA; Wijbrandts CA; Tak PP; Nurmohamed MT; Voskuyl AE; Frings-Dresen MH
    Scand J Rheumatol; 2009; 38(4):246-50. PubMed ID: 19337948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic evaluation of tocilizumab monotherapy compared to adalimumab monotherapy in the treatment of severe active rheumatoid arthritis.
    Carlson JJ; Ogale S; Dejonckheere F; Sullivan SD
    Value Health; 2015 Mar; 18(2):173-9. PubMed ID: 25773552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacoeconomics of drug therapy for rheumatoid arthritis.
    Tugwell P
    Rheumatology (Oxford); 2000 Jun; 39 Suppl 1():43-7. PubMed ID: 11001379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of combination nonbiologic disease-modifying antirheumatic drug strategies in patients with early rheumatoid arthritis.
    Tosh JC; Wailoo AJ; Scott DL; Deighton CM
    J Rheumatol; 2011 Aug; 38(8):1593-600. PubMed ID: 21572149
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incorporating considerations of cost-effectiveness, affordability, and resource implications in guideline development: article 6 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report.
    Hill SR; Olson LG; Falck-Ytter Y; Cruz AA; Atkins D; Baumann M; Jaeschke R; Woitalla T; Schünemann HJ;
    Proc Am Thorac Soc; 2012 Dec; 9(5):251-5. PubMed ID: 23256167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis.
    Furneri G; Mantovani LG; Belisari A; Mosca M; Cristiani M; Bellelli S; Cortesi PA; Turchetti G
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S72-84. PubMed ID: 23072761
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analyses of cost data in economic evaluations conducted alongside randomized controlled trials.
    Doshi JA; Glick HA; Polsky D
    Value Health; 2006; 9(5):334-40. PubMed ID: 16961551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Medical and economic aspects of rheumatoid arthritis].
    Fautrel B; Gaujoux-Viala C
    Bull Acad Natl Med; 2012 Oct; 196(7):1295-305; discussion 1305-6. PubMed ID: 23815015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The issue of comparators in economic evaluations of biologic response modifiers in rheumatoid arthritis.
    Tsao NW; Bansback NJ; Shojania K; Marra CA
    Best Pract Res Clin Rheumatol; 2012 Oct; 26(5):659-76. PubMed ID: 23218430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.